Skip to main content
SpringerLink
Log in

Selective serotonin re-uptake inhibitors in anxiety disorders: room for improvement

  • Chapter
Anxiolytics

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

As a group, the SSRIs have been found efficacious in double-blind placebo-controlled studies across a range of depressive disorders, both in short-term and long-term treatment. The efficacy of SSRIs is similar to that of tricyclic antidepressants (TCAs) in patients with major depression, apart from in the subgroup of hospitalised in-patients, where TCAs are marginally, but significantly, more effective [1]. In randomised controlled trials, the tolerability of SSRIs is better than that of TCAs, there being significantly fewer drop-outs from treatment because of adverse effects, but the magnitude of this difference is rather small [2]. SSRIs are clearly safer than most TCAs, when taken in overdose; and being less sedative, are less likely to interfere with many aspects of everyday life. For these reasons, the SSRIs have gained widespread acceptance in the treatment of depression, both in primary and secondary care settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson IM (1998) SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.Depression and Anxiety7 [suppl 1]: 11–17

    Article  PubMed  Google Scholar 

  2. Anderson 1M, Tomenson BM (1999) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.J Affect Disord; in press

    Google Scholar 

  3. Tollefson GD, Greist JH, Jefferson JW, Heiligenstein JH, Sayler ME, Tollefson SL, Koback K (1994) Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine.J Clin Psychopharmacol14: 385–391

    PubMed  CAS  Google Scholar 

  4. Nutt DJ, George DT (1990) Serotonin and anxiety. In: GD Burrows, M Roth, R Noyes (eds):Handbook of anxiety, Vol. 3, the neurobiology of anxiety. Elsevier, Amsterdam, 189–221

    Google Scholar 

  5. Bell CJ, Nutt DJ (1998) Serotonin and panic.Brit J Psychiat172: 465–471

    Article  PubMed  CAS  Google Scholar 

  6. Deakin JFW, Graeff FG (1991) 5-HT and mechanisms of defence.J Psychopharmacol5: 305–315

    Article  PubMed  CAS  Google Scholar 

  7. Fineberg NA, Roberts A, Montgomery SA, Cowen PT (1997) Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine.Brit J Psychiat171: 280–282

    Article  PubMed  CAS  Google Scholar 

  8. Baldwin DS, Rudge SE (1995) The role of serotonin in depression and anxiety.Int Clin Psychopharmacol9 (suppl. 4): 41–45

    Article  PubMed  Google Scholar 

  9. Evans L, Kennardy J, Schneider P, Hoey H (1986) Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks: a double blind comparison of zimelidine, imipramine and placebo.Acta Psychiat Scand73: 49–53

    Article  PubMed  CAS  Google Scholar 

  10. Nilsson BS (1983) Adverse reactions in connection with zimelidine treatment: a review.Acta Psychiat Scand308 (suppl): 115–119

    CAS  Google Scholar 

  11. den Boer JA, Westenberg HG, Kamerbeek WD, Verhoeven WM, Kahn RS (1987) Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine.Int Clin Psychopharmacol2: 21–32

    Article  Google Scholar 

  12. den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline.Int Clin Psychopharmacol3: 59–74

    Article  Google Scholar 

  13. den Boer JA, Westenberg HG (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.Psychopharmacology (Berlin)102: 85–94

    Article  Google Scholar 

  14. Hoehn-Saric R, McLeod DR, Hipsley PA (1993) Effect of fluvoxamine on panic disorder.J Clin Psychopharmacol13: 321–326

    Article  PubMed  CAS  Google Scholar 

  15. Woods S, Black D, Brown S et al. (1994) Fluvoxamine in the treatment of panic disorder in outpatients: a double-blind, placebo-controlled study. Presented at the Annual Meeting of the College of International Neuropsychopharmacology, Washington DC

    Google Scholar 

  16. Sandmann J, Lorch B, Bandelow B, Hartter S, Winter P, Hiemke C, Benkert 0 (1988) Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.Pharmacopsychiatry31:: 117–121

    Google Scholar 

  17. Nair NP, Bakish D, Saxena B, Amin M, Schwartz G, West TE (1996) Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.Anxiety2: 192–198

    Article  PubMed  CAS  Google Scholar 

  18. Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, Thibaudeau C, Raine D (1996) A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.Psychopharmacol Bull32: 135–141

    PubMed  CAS  Google Scholar 

  19. Van Vliet IM, Den Boer Westenberg HG, Slaap BR (1996) A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.J Clin Psychopharmacol16: 299–306

    Article  PubMed  Google Scholar 

  20. Black DW Wesner R, Bowers W, Gad J (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.Arch Gen Psychiat50: 44–50

    Article  Google Scholar 

  21. Sharp DM, Power KG, Simpson RI, Swanson V, Moodie E, Anstee JA, Ashford JJ (1997) Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia in primary care.Brit J Gen Pract47: 150–155

    CAS  Google Scholar 

  22. Black DW, Wesner R, Bowers W, Monahan P, Gabel J (1995) Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms.Ann Clin Psychiat7: 181–188

    Article  CAS  Google Scholar 

  23. Black DW, Monahan P, Wesner R, Gabel J, Bowers W (1996) The effect of fluvoxamine, cognitive therapy, and placebo on abnormal personality traits in 44 patients with panic disorder.J Personality Disord10: 185–194

    Article  Google Scholar 

  24. Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA (1997) Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care.Brit J Gen Pract47: 150–155

    CAS  Google Scholar 

  25. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD, the Fluoxetine Panic Disorder Study Group (1998) Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo.Amer J of Psychiat155: 1570–1577

    CAS  Google Scholar 

  26. Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson, the Fluoxetine Panic Disorder Study Group (1999) Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine.Brit J Psychiat174: 213–218

    Article  PubMed  CAS  Google Scholar 

  27. Bystritsky A, Rosen RM, Murphy KJ, Bohn P, Keys SA, Vapnik T. (1994–1995) Double-blind pilot trial of desipramine versus fluoxetine in panic patients.Anxiety1:1994–1995

    Google Scholar 

  28. Oehrberg S, Christiansen PE, Behnke E, Borup AL, Sverin B, Soegaard J, Callberg H, Judge R, Ohrstrom JK, Manniche PM (1995) Paroxetine in the treatment of panic disorder. A randomised double-blind, placebo-controlled study.Brit J Psychiat167: 374–379

    Article  PubMed  CAS  Google Scholar 

  29. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998) Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.Amer J of Psychiat155: 36–42

    CAS  Google Scholar 

  30. Lecrubier Y, Bakker A, Dunbar G, Judge R (1997) A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators.Acta Psychiat Scand95: 145–152

    Article  PubMed  CAS  Google Scholar 

  31. Lecrubier Y, Judge R (1997) Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators.Acta Psychiat Scand95: 153–160

    Article  PubMed  CAS  Google Scholar 

  32. Burnham DB, Steiner MX, Gergle IP et al. (1995) Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: a double-blind study. Presented in poster session at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico

    Google Scholar 

  33. Pohl RB, Wolkow RM, Clary CM (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial.Amer J of Psychiat155: 1189–1195

    CAS  Google Scholar 

  34. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998) Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.Arch Gen Psychiat55: 1010–1016

    Article  PubMed  CAS  Google Scholar 

  35. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C (1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation.Brit J Psychiat173: 54–60

    Article  PubMed  CAS  Google Scholar 

  36. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997) The effect of citalopram in panic disorder.Brit J Psychiat179: 549–553

    Article  Google Scholar 

  37. Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, Pettinen JTT, Pedersen T

    Google Scholar 

  38. Lehto HJ (1998) A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.J Clin Psychiat59: 528–534

    Google Scholar 

  39. den Boer JA (1998) Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint.J Clin Psychiat59 (suppl 8]: 30–36

    Google Scholar 

  40. Boyer W (1995) Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.Int Clin Psychopharmacol10: 45–49

    Article  CAS  Google Scholar 

  41. Baldwin DS, Birtwistle J (1998) The side-effect burden associated with drug treatment of panic disorder.J Clin Psychiat59 (suppl 8]: 39–44

    CAS  Google Scholar 

  42. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E (1997) Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.J Clin Psychopharmacol17: 4–10

    Article  PubMed  CAS  Google Scholar 

  43. Perse TL, Greist JH, Jefferson JW, Rosenfeld R, Dar R (1987) Fluvoxamine treatment of obsessive-compulsive disorder.Amer J of Psychiat144: 1543–1548

    CAS  Google Scholar 

  44. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989) Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.Arch Gen Psychiat46: 36–44

    Article  PubMed  CAS  Google Scholar 

  45. Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, Douge R, Cialdella P (1990) A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.Int Clin Psychopharmacol5: 17–30

    Article  PubMed  CAS  Google Scholar 

  46. Cottraux J, Mollard E, Bouvard M, Marks I (1993) Exposure therapy, fluvoxamine, or combina-tion treatment in obsessive-compulsive disorder: one-year follow-up.Psychiat Res49: 63–75

    Article  CAS  Google Scholar 

  47. Greist JH, Jenike MA, Robinson DS, Rasmussen SA (1995) Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial.Eur J Clin Res7: 195–204

    Google Scholar 

  48. Goodman WK, Kozak MJ, Liebowitz M, White KL (1996) Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.Int Clin Psychopharmacol11: 21–29

    Article  PubMed  CAS  Google Scholar 

  49. Freeman CP, Trimble MR, Deakin JF, Stokes TM, Ashford JJ (1994) Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.J Clin Psychiat55: 301–305

    CAS  Google Scholar 

  50. Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA (1996) Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.J Clin Psychopharmacol16: 121–129

    Article  PubMed  CAS  Google Scholar 

  51. Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB (1997) A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.Int Clin Psychopharmacol12: 131–136

    Article  PubMed  CAS  Google Scholar 

  52. Hohagen F, Winkelmann G, Rasche-Rule H, Hand I, Konig A, Munchau N, Hiss H, GeigerKabisch C, Kappler C, Schramm P et al (1998) Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study.Brit J Psychiat35: 71–78

    Google Scholar 

  53. van Balkom AJLM, de Haan E, van Oppen P, Spinhoven P, Hoogduin KAL, van Dyck R (1998) Cognitive and behavioural therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder.J New Ment Dis186: 492–499

    Article  Google Scholar 

  54. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.Eur Neuropsychopharmacol3: 143–152

    Article  PubMed  CAS  Google Scholar 

  55. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Komiguez RA, Koran LM, Shear MK, Goodman WK, Genduso LA (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.Arch Gen Psychiat51: 559–567

    Article  PubMed  CAS  Google Scholar 

  56. Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ (1992) Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.J Amer Acad Child Adolesc Psychiat31: 1062–1069

    Article  CAS  Google Scholar 

  57. Tollefson GD, Birkett M, Koran L, Genduso L (1994) Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.J Clin Psychiat55 (suppl): 69–76

    Google Scholar 

  58. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1996) Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).Psychopharmacol. Bull.32: 167–173

    PubMed  CAS  Google Scholar 

  59. Romano S, Goodman WK, Tamura R, Gonzalez J and Collaborative Research Group. Long-term treatment of obsessive compulsive disorder following acute response: a comparison of fluoxetine versus placebo;submitted for publication

    Google Scholar 

  60. Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML (1997) Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.Amer J of Psychiat154: 1261–1264

    CAS  Google Scholar 

  61. Lopez-Ibor JJ Jr, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, Hernandez M, Gomez-Perez JC (1996) Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder.Eur Neuropsychopharmacol6: 111–118

    Article  PubMed  CAS  Google Scholar 

  62. Wheadon D, Bushnell WD, Steiner M (1993) A fixed dose comparison of 20, 40 or 60 mg of paroxetine in the treatment of obsessive-compulsive disorder. Presented at the American College of Neuropsychopharmacology Annual Meeting, Puerto Rico, December

    Google Scholar 

  63. Dunbar GC, Steiner M, Bushnell WD, Gergel I, Wheadon DE (1995) Long term treatment and prevention of obsessive compulsive disorder with paroxetine.Eur Neuropsychopharmacol5: 372

    Article  Google Scholar 

  64. Zohar J, Judge R (1996) Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.Brit J Psychiat169: 468–474

    Article  PubMed  CAS  Google Scholar 

  65. Chouinard G, Goodman WK, Greist J, Jenike M, Rasmussen S, White K (1990) Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.Psychopharmacol. Bull.26:279–284

    PubMed  CAS  Google Scholar 

  66. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D et al (1999) Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.J Clin Psychopharmacol19: 172–176

    Article  PubMed  CAS  Google Scholar 

  67. Greist JH, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K et al (1995) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.Arch Gen Psychiat52: 289–295

    Article  PubMed  CAS  Google Scholar 

  68. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard B et al (1995) A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder.Int Clin Psychopharmacol10: 57–65

    Article  PubMed  CAS  Google Scholar 

  69. Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM (1997) A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.Int Clin Psychopharmacol12: 309–316

    Article  PubMed  CAS  Google Scholar 

  70. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B et al (1998) Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.J Amer Med Assoc280: 1752–1756

    Article  CAS  Google Scholar 

  71. Bisserbe JC, Lane RM, Flament MF (1997) A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.Eur Psychiat12: 82–93

    Article  CAS  Google Scholar 

  72. Mundo E, Bianchi L, Bellodi L (1997) Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.J Clin Psychopharmacol17: 267–271

    Article  PubMed  CAS  Google Scholar 

  73. Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995) Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.Brit J Psychiat166: 424–443

    Article  PubMed  CAS  Google Scholar 

  74. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC (1995) Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder.Arch Gen Psychiat52: 53–60

    Article  PubMed  CAS  Google Scholar 

  75. Stein DJ, Spadaccini E, Hollander E (1995) Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder.Int Clin Psychopharmacol10: 11–18

    Article  PubMed  CAS  Google Scholar 

  76. Pigott TA, Seay SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.J Clin Psychiat60: 101–106

    Article  CAS  Google Scholar 

  77. van Vliet IM, den Boer JA, Westenberg HG (1994) Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine.Psychopharmacology(Berlin) 115: 128–134

    Article  Google Scholar 

  78. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999) Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.Amer J of Psychiat156: 756–760

    CAS  Google Scholar 

  79. Black B, Uhde TW (1994) Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study.JAmerAcad Child Adolesc Psychiat33: 701–703

    Google Scholar 

  80. Stein MB, Liebowitz Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.J Amer Med Assoc280: 708–713

    Article  CAS  Google Scholar 

  81. Baldwin DS, Bobes J, Stein DJ, Scharwachter I, Faure M (1999) Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study.Brit J Psychiat175: 120–126

    Article  PubMed  CAS  Google Scholar 

  82. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, Walker JR (1996) Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.J Clin Psychopharmacol16: 218–222

    Article  PubMed  CAS  Google Scholar 

  83. Katzelnick DJ, Kobak KA, Greist JH, Jefferson W, Mantle JM, Serlin RC (1995) Sertraline for social phobia: a double-blind placebo-controlled crossover study.Amer J of Psychiat152: 1368–1371

    CAS  Google Scholar 

  84. Van Ameringen M, Mancini C, Streiner D (1994) Sertraline in social phobia.J Affect Disord31: 141–5

    Article  PubMed  Google Scholar 

  85. van der Kolk BA, Dreyfus D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G (1994) Fluoxetine in posttraumatic stress disorder.J Clin Psychiat55: 517–522

    Google Scholar 

  86. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JRT (1999) Fluoxetine in post-traumatic stress disorder. A randomised double-blind study.Brit J Psychiat175: 17–22

    Article  PubMed  CAS  Google Scholar 

  87. Davidson J, van der Kolk Brady K, Rothbaum B, Sikes C, Farfel G (1997) Double-blind comparison of sertraline and placebo in patients with post-traumatic stress disorder. Presented at 10th ECNP, Vienna, Austria, September

    Google Scholar 

  88. Baker D, Brady K, Goldstein S, Farfel G (1998) Double-blind flexible-dose multicenter study of sertraline and placebo in outpatients with post-traumatic stress disorder. Presented at American College of Neuropsychopharmacology, Puerto Rico, December

    Google Scholar 

  89. Pigott TA, L’Heureux F, Hill JL, Bihari K, Berstein SE, Murphy DL (1992) A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder.J Clin Psychopharmacol12: 11–18

    CAS  Google Scholar 

  90. Grady TA, Pigott TA, L’Heureux F, Hill JL, Berstein SE, Murphy DL (1993) Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.Amer J of Psychiat150: 819–821

    CAS  Google Scholar 

  91. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH (1993) Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.Amer J of Psychiat150: 647–649

    CAS  Google Scholar 

  92. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR (1991) A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.J Clin Psychopharmacol11: 175–184

    Article  PubMed  CAS  Google Scholar 

  93. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.Arch Gen Psychiat51: 302–308

    Article  PubMed  CAS  Google Scholar 

  94. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH (1997) Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.Amer J of Psychiat154: 1293–1295

    CAS  Google Scholar 

  95. Mundo E, Gugliemo E, Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.lilt Clin Psychopharmacol13: 219–224

    Article  CAS  Google Scholar 

  96. Slaap BR, van Vliet IM, Westenberg HG, den Boer JA (1995) Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).J Affect Disord33: 31–38

    Article  PubMed  CAS  Google Scholar 

  97. Slaap BR, van Vliet IM, Westenberg HG, Den Boer JA (1996) Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response.J Affect Disord39: 13–19

    Article  PubMed  CAS  Google Scholar 

  98. Slaap BR, van Vliet IM, Westenberg HG, Den Boer JA (1996) MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients. A preliminary report.Psychopharmacology(Berlin) 127: 353–358

    CAS  Google Scholar 

  99. Thienemann M, Koran LM (1995) Do soft signs predict treatment outcome in obsessive-compulsive disorder?J Neuropsychiat Clin Neurosci7: 218–222

    CAS  Google Scholar 

  100. Baldwin DS, Thomas SC, Birtwistle J (1997) Effects of antidepressant drugs on sexual function.Int J Psychiat Clin Pract1: 47–58

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mental Health Group, Faculty of Medicine, Health and Biological Sciences, University of Southampton, UK

    David S. Baldwin

  2. Primary Medical Care Group, Faculty of Medicine, Health and Biological Sciences, University of Southampton, UK

    Jon Birtwistle

Authors
  1. David S. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jon Birtwistle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut de Recherche Pierre Fabre, Parc Industriel de la Chartreuse, Castres, 81100, France

    Mike Briley

  2. Psychopharmacology Unit School of Medical Science, University of Bristol, University Walk, Bristol, BS8 1TD, UK

    David Nutt

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Baldwin, D.S., Birtwistle, J. (2000). Selective serotonin re-uptake inhibitors in anxiety disorders: room for improvement. In: Briley, M., Nutt, D. (eds) Anxiolytics. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8470-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8470-9_5

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9581-1

  • Online ISBN: 978-3-0348-8470-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation